Table 1. Characteristics of Included Studies

Author (Year) Type and range of burns Sample size (T/C) Treatment group Control group Treatment period Outcomes Results Safety
Nation Study design
Cui et al10) (1999) 1) TG49.9±18.8%, 3rddegree 27.1±13.7%2) CG48.8±17.1%, 3rddegree 26.±12.9% 20(10/10) 10㎖ of herbal medicine Tid General treatment 20 days 1) PBL prolifer-ation2) IL-2 production(u/㎖)3) wound healing time 1) p<0.01 (TG>CG)7.89±3.89>1.89±0.302) p<0.01 (TG>CG)1453.0±113.8>971.3±112.53) 30.7±10.3d(TG)<37.4±9.5d(CG) sepsis(1), kidney failure(1) in CG
China CT
Ghasemali et al11) (2009) 2nd degree19.8±7.9% 60 (30/30) Aloe cream Bid SSD 1% cream Bid 19 days 1) wound healing time2) wound size3) infection 1) p<0.000115.9±2d(TG)<18.73±2.65d(CG)2) p<0.013) negative
Iran RCT
LV et al12) (2010) 2nd, 3rd degree1) TG 57.6% (residual 7.4%)2) CG 56.5% (residual 6.9%) 128 (70/58) TCM bath + bFGF/TCM burn ointment Qod Chlorhexidine solution cleaning + SSD cream Qod until fully healed 1) pain(VRS)2) wound healing time3) rate of scar formation 1) p<0.05 (TG<CG)2) p<0.05 (TG<CG)13.45±4.74d<23.87±14.45d3) p<0.05 (TG<CG)21.4%<60.3%
China CT
Vilelmine et al13) (2011) 2nd degree1) TG10.26±4.37%2) CG9.89±4.89% 211(S54,D50/S55,D52) MEBO, Povidone Iodine Bid Povidone Iodine for 3-4 day, Bepanthenol cream Bid 18 days 1) hospitalization time2) time of 50% wound healing time3) cost4) pain (VAS) 1) p=0.02 (TG<CG)3.24±2.1d<4.20±2.1d2) p=0.008.7±3.0d(TG)<10.75±3.8d(CG)3) superficial partial (p=0.00)€483.21(TG)<€551.13(CG)4) p=0.00 infection, fever, allergy(p=0.07): TG(n=11), CG(n=8)
Greece RCT
Wen et al14) (2012) 1) TG40.38±10.57㎠2) CG38.58±10.52㎠ 80 (43/37) Wuhuang traditional Chinese medicine bath for 30 minutes Qod tap water bath for 30 minutes Qod 21 days 1) wound healing time2) healing rate 1) p<0.05 (TG<CG)30±12d<40±16d2) p<0.05TG : effective 28(65.13%) valid 10(23.25%) invalid 5(11.63%)CG : effective 18(59.46%) valid 8(24.32%) invalid 11(16.23%)
China CT
Jing et al15) (2014) 2nd degree1) TGS:7.04±3.41%D:6.54±2.06%2) CGS:6.85±3.21%D:6.94±2.59% 240 (S72,D48/S72,D48) FXBO ointment(5g/80㎠)Qd or Qod blank ointment(5g/80㎠)Qd or Qod 28 days 1) healing rate2) median healing time3) effective rate 1) more effective in TG(S : p=0.000, D : p=0.025)2) more shorter in TG(S : p=0.000, D : p=0.009)3) more effective in TG(S : p=0.035, D : p=0.003) adverse eventsTG(n=13; 8.33%)CG(n=15; 7.50%)
China RCT
Jiang et al16) (2015) more than 50%1) TG10.06±0.38㎠(n=10)2) CG10.18±0.53㎠(n=10) 60 (30/30) Traditional Chinese medicine dressing for 2 minutes Qd Rifampicin + 0.9% saline solution dressing for 2 minutes Qd 14 days 1) wound healing rate2) pain (VAS)3) bacterial culture 1) p=0.001 (TG>CG)86.33±9.18>78.57±8.402) p=0.028(7d), p>0.05(14d)3) p>0.05 none
China CT
Lin17) (2016) 2nd-3rd degree 208 (126/82) Traditional Chinese medicine based on syndrome differentiation + for external use General treatment none stated 1) pain (duration)2) scar formation3) shock p<0.051) 77.8%(TG)>28.6%(CG)2) 4.8%(TG)<13.4%(CG)3) 0%(TG)<4.9%(CG) risk of infection :6.3%(TG)<31.7%(CG)
China CT
Ebrahim et al18) (2016) 2nd degree3.7±2.4% 90 (45/45) AEO 10% cream Qd SSD 1% cream Qd 30 days 1) wound healing time2) general wound appearance3) burning, itching, warming score (VAS)4) satisfaction grade 1) p=0.001 (TG<CG)13.9±5.3d<17.5±6.9d2) p<0.001 : 7, 10th d3) p<0.05higher burning, pain in CG, higher warming in TG4) p<0.001 (TG>CG)7.2±1.8>5.3±1.7 no allergyrisk of skin graft : 2.2%(TG)<6.7%(CG), RR:0.33risk of infection : TG<CG
Iran RCT
Amin et al19) (2017) 2nd degreelesser than 10% 75 (40/35) Centiderm ointment Qd SSD 1% cream until fully healed 1) time of re-epithelialization2) wound healing time3) objective index4) subjective index 1) p=0.001 (TG<CG)13.7±1.48d<20.67±2.02d2) p=0.001 (TG<CG)14.67±1.78d<21.53±1.65d3,4) p<0.05 (TG<CG) CG : infection(n=4)
Iran RCT
Du20) (2018) 3rd degree1) TG40.81±12.52%(residual 6.91±2.54%)2) CG41.67±11.38%(residual 6.13±2.47%) 80 (40/40) Traditional Chinese medicine bath + dressing, ointment Qod SSD 1% cream Qod until fully healed 1) healing rate (2 weeks)2) pain relief (VRS)3) bacterial clearance rate4) scar formation5) wound healing time 1) p<0.05 (TG>CG)97.5%>72.5%2) p<0.05 (TG>CG)75.0%>40.0%3) p<0.05 (TG>CG)82.5%>40.0%4) p<0.05 (TG<CG)17.5%<52.5%5) p<0.05 (TG<CG)12.49±2.51d<23.42±3.51d
China CT
Shi et al21) (2018) 2nd-3rd degree1) TG7.1±0.5%2) CG7.3±0.6% 84 (42/42) Traditional Chinese medicine bath for 30-60 minutes + bFGF Qod SSD cream Qod until fully healed 1) pain (Jusodongtongbu ngeupbeop)2) woundhealing time3) scar formation 1) p<0.05 (TG>CG)95.2%>85.7%2) p<0.05 (TG<CG)13.44±4.62d<21.78±5.09d3) p<0.05 (TG<CG)14.3%<40.5%
China CT
Chen et al22) (2019) deep 2nd degree1) TG<5%(39),<10%(17)2) CG<5%(42),<10%(14) 112 (56/56) Zhangpi ointment Qd SSD 1% cream Qd 21 days 1) healing rate2) wound healing time3) pain (VAS) 1) p<0.05 (TG>CG)92.9%>73.2%2) p<0.05 (TG<CG)20.3±2.9d<26.9±3.2d3) p<0.05
China CT
Wang23) (2019) 1) TG18.5±3.2%2) CG15.8±2.7% 117 (59/58) Traditional Chinese medicine bath for 30 minutes + bFGF+Hwasanghaedokje Chlorhexidine solution cleaning + SSD 1% cream 14 days 1) wound healing time2) scar formation3) pain (temporary scale)4) serum inflam-matory indexes(IL-6, TNF-α) 1) p<0.05 (TG<CG)13.2±3.4d<24.1±5.7d2) p<0.05 (TG<CG)3.4%<32.8%3) p<0.05 (TG<CG)4) p<0.05 (TG<CG)
China CT
AEO : Arnebia Euchroma Ointment
bFGF : basic Fibroblast Growth Factor
CG : Control group
CT : Clinical Trials
D : Deep partial thickness burns
d : day
€ : Euro
FXBO : Fufang Xuelian Burn Ointment
GWA : General Wound Appearance
IL-2 : Interleukin-2
IL-6 : Interleukin-6
MEBO : Moist Exposed Burn Ointment
RCT : Randomized Controlled Trials
S : Superficial partial thickness burns
SSD : Silver Sulfadiazine
TBSA : Total Burn Surface Area
TG : Treatment group
TNF-α : Tumor Necrosis Factor-α
VAS : Visual Analogue Scale
VRS : Verbal Rating Scale